http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 31 Aug 2026 08:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/AEON+Biopharma+to+Participate+in+Lake+Street+Capital+Markets%E2%80%99+10th+Annual+Best+Ideas+Growth+%28BIG10%29+Conference/27001296.html <p align="justify">ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.</p> <p align="justify">To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.</p> http://www.streetinsider.com/Press+Releases/AEON+Biopharma+to+Participate+in+Lake+Street+Capital+Markets%E2%80%99+10th+Annual+Best+Ideas+Growth+%28BIG10%29+Conference/27001296.html Mon, 31 Aug 2026 08:00:00 -0400 AEON http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+to+Participate+in+Lake+Street+Capital+Markets%E2%80%99+10th+Annual+Best+Ideas+Growth+%28BIG10%29+Conference/27001296.html <p align="justify">ALISO VIEJO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, announced today that AEON management will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 10th Annual Best Ideas Growth (BIG10) Conference being held in New York City on Thursday, September 10th, 2026.</p> <p align="justify">To receive additional information about the Conference, request an invitation or to schedule a one-on-one meeting, please contact your Lake Street Representative.</p> http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+to+Participate+in+Lake+Street+Capital+Markets%E2%80%99+10th+Annual+Best+Ideas+Growth+%28BIG10%29+Conference/27001296.html Mon, 31 Aug 2026 08:00:00 -0400 AEON http://www.streetinsider.com/Corporate+News/AEON+Biopharma+names+ex-FDA+neuroscience+official+as+acting+CRO/26964451.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has designated Paul Lee, M.D., Ph.D., a former senior official at the U.S. Food and Drug Administration, as acting Chief Regulatory Officer, according to a company statement.</p><p>Dr. Lee will serve in the role through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, which has previously advised AEON on regulatory strategy for its lead candidate, ABP-450. He will lead regulatory strategy, oversee FDA interactions, and work with AEON's analytical, chemistry, manufacturing and controls, and clinical teams as the company advances ABP-450 under the 351(k) biosimilar pathway.</p><p>Dr. Lee spent more than seven years at http://www.streetinsider.com/Corporate+News/AEON+Biopharma+names+ex-FDA+neuroscience+official+as+acting+CRO/26964451.html Mon, 24 Aug 2026 08:01:21 -0400 AEON http://www.streetinsider.com/Management+Changes/AEON+Biopharma+names+ex-FDA+neuroscience+official+as+acting+CRO/26964451.html <p>AEON Biopharma, Inc. (NYSE American: AEON) has designated Paul Lee, M.D., Ph.D., a former senior official at the U.S. Food and Drug Administration, as acting Chief Regulatory Officer, according to a company statement.</p><p>Dr. Lee will serve in the role through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, which has previously advised AEON on regulatory strategy for its lead candidate, ABP-450. He will lead regulatory strategy, oversee FDA interactions, and work with AEON's analytical, chemistry, manufacturing and controls, and clinical teams as the company advances ABP-450 under the 351(k) biosimilar pathway.</p><p>Dr. Lee spent more than seven years at http://www.streetinsider.com/Management+Changes/AEON+Biopharma+names+ex-FDA+neuroscience+official+as+acting+CRO/26964451.html Mon, 24 Aug 2026 08:01:21 -0400 AEON http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Press+Releases/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html <p align="center"><em>- Former Deputy Director of the FDA’s Office of Neuroscience </em></p> <p align="center"><em>- </em><em>Dr. Lee has previously advised AEON through Clintrex Research LLC (Clintrex), an affiliate of BlueRidge Life Sciences, on the regulatory strategy for ABP-450</em></p> <p align="justify">ALISO VIEJO, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, today announced the designation of Paul Lee, M.D., Ph.D. as the Company’s acting Chief Regulatory Officer, through Clintrex, strengthening the http://www.streetinsider.com/Globe+Newswire/AEON+Biopharma+Designates+Former+FDA+Neuroscience+Leader+Paul+Lee%2C+M.D.%2C+Ph.D.+as+Acting+Chief+Regulatory+Officer/26964401.html Mon, 24 Aug 2026 08:00:00 -0400 A.26342942 AEON O.22095645 O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962750.html si-local-file:///var/storage/secattach/20260821/26962750.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962750.html Fri, 21 Aug 2026 19:41:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962750.html si-local-file:///var/storage/secattach/20260821/26962750.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962750.html Fri, 21 Aug 2026 19:41:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962746.html si-local-file:///var/storage/secattach/20260821/26962746.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962746.html Fri, 21 Aug 2026 19:38:00 -0400 AEON O.49558857 http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962746.html si-local-file:///var/storage/secattach/20260821/26962746.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++AEON+Biopharma%2C+Inc.++++++For%3A+Aug+19++Filed+by%3A+LYNCH+TIMOTHY+P/26962746.html Fri, 21 Aug 2026 19:38:00 -0400 AEON O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Press+Releases/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html <p align="center"><em>- Complementary peptide-mapping methods increased coverage of the active botulinum neurotoxin primary sequence from approximately 93% to 98%, with 100% amino acid identity across all regions analyzed </em></p> <p align="center"><em>- Preliminary analysis demonstrates preservation of the critical disulfide bond architecture required for toxin activation </em></p> <p align="center"><em>- Primary amino acid sequence and disulfide connectivity are foundational to establishing molecular similarity between ABP-450 and BOTOX</em>®</p> <p align="center"><em>- FDA feedback from planned Biosimilar Biological Product Development (BPD) Type 2b interaction expected to help inform the next phase of ABP-450 development </em></p> http://www.streetinsider.com/Globe+Newswire/AEON+Reports+Expanded+Structural+Data+Supporting+Molecular+Similarity+of+ABP-450+to+BOTOX%C2%AE/26947433.html Wed, 19 Aug 2026 08:00:00 -0400 A.06822034 AEON O.20026344 O.49558857 http://www.streetinsider.com/Analyst+PT+Change/AEON+Biopharma%2C+Inc+%28AEON%29+PT+Lowered+to+%241.20+at+H.C.+Wainwright/26934556.html (Updated - August 17, 2026 6:49 AM EDT) <p>H.C. Wainwright analyst Douglas Tsao lowered the price target on AEON Biopharma, Inc (NYSE: AEON) to $1.20 (from $5.00) while maintaining a Buy rating.</p><p>The analyst commented: "ABP-450's biosimilar development remains in the analytical phase of the FDA's 351(k) pathway. Aeon held a Type 2a meeting with the FDA in the first quarter, where the agency reviewed the company's proposed analytical similarity strategy and gave feedback supporting the planned analytical approach, while acknowledging the difficulty of characterizing the 900 kDa botulinum toxin complex. That feedback is offered directional support for the analytical plan, but http://www.streetinsider.com/Analyst+PT+Change/AEON+Biopharma%2C+Inc+%28AEON%29+PT+Lowered+to+%241.20+at+H.C.+Wainwright/26934556.html Mon, 17 Aug 2026 06:49:53 -0400 AEON